Fig. 5. YD and EGFR-TKIs synergistically inhibit the growth in acquired gefitinib-resistant PDX models.

When tumor volumes reached 200 to 250 mm3, mice engrafted with YHIM-1009 tumors were segregated into appropriate treatment groups (three to five mice per group). Mice were orally administered with compounds every day for 31 days and doses indicated are 1 mg/kg for YD, 10 mg/kg for gefitinib (a). *P < 0.05, **P < 0.01, ***P < 0.005 by t-test